PMSNF (Proteome Sciences) Cyclically Adjusted Revenue per Share: $0.03 (As of Dec. 2025)


What is Proteome Sciences Cyclically Adjusted Revenue per Share?

Proteome Sciences PMSNF Cyclically Adjusted Revenue per Share is $0.03 as of Dec. 2025. The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Proteome Sciences's adjusted revenue per share data for the fiscal year that ended in Dec. 2025 was $0.016. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.03 for the trailing ten years ended in Dec. 2025.

During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 17.20% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 5.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Proteome Sciences was 26.00% per year. The lowest was -20.60% per year. And the median was 0.00% per year.

As of today (2026-07-02), Proteome Sciences's current stock price is $ 0.02475. Proteome Sciences's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec. 2025 was $0.03. Proteome Sciences's Cyclically Adjusted PS Ratio of today is 0.83.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Proteome Sciences was 20.00. The lowest was 0.69. And the median was 2.03.


Proteome Sciences  (OTCPK:PMSNF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Proteome Sciences's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.02475/0.03
=0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Proteome Sciences was 20.00. The lowest was 0.69. And the median was 2.03.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Proteome Sciences Cyclically Adjusted Revenue per Share Related Terms


Proteome Sciences Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Proteome Sciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Proteome Sciences Cyclically Adjusted Revenue per Share Chart

Proteome Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.03 0.01 0.03 0.03

Proteome Sciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.00 0.03 0.00 0.03

PMSNF vs TMO, DHR, IDXX: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Proteome Sciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Proteome Sciences Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Proteome Sciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Proteome Sciences's Cyclically Adjusted PS Ratio falls into.



Proteome Sciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Proteome Sciences's adjusted Revenue per Share data for the fiscal year that ended in Dec. 2025 was:

Adj_RevenuePerShare=Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=0.016/139.9000*139.9000
=0.016

Current CPI (Dec. 2025) = 139.9000.

Proteome Sciences Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201612 0.014 102.200 0.019
201712 0.015 105.000 0.020
201812 0.013 107.100 0.017
201912 0.021 108.500 0.027
202012 0.022 109.400 0.028
202112 0.023 114.700 0.028
202212 0.031 125.300 0.035
202312 0.020 130.500 0.021
202412 0.020 135.100 0.021
202512 0.016 139.900 0.016

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.03 mean?
Proteome Sciences (PMSNF) has a Cyclically Adjusted Revenue per Share of $0.03 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Proteome Sciences and its competitors.
Is Proteome Sciences' Cyclically Adjusted Revenue per Share too high?
Proteome Sciences' current Cyclically Adjusted Revenue per Share is $0.03.
How does Proteome Sciences' Cyclically Adjusted Revenue per Share compare to TMO and DHR?
Proteome Sciences' Cyclically Adjusted Revenue per Share of $0.03 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Proteome Sciences and its competitors. Proteome Sciences's current Cyclically Adjusted Revenue per Share is $0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteome Sciences stock overvalued right now?
Proteome Sciences (PMSNF) has a current Cyclically Adjusted Revenue per Share of $0.03. The stock's GF Value™ is $0.03, compared to a current price of $0.02 — trading 17.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $0.03. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Proteome Sciences (PMSNF), the current Cyclically Adjusted Revenue per Share is $0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Proteome Sciences Business Description

Other Exchanges PRMl:UKPRM:UKPI2:Germany
Address Downside Bridge Road, Coveham House, Cobham, Surrey, GBR, KT11 3EP
Proteome Sciences PLC is engaged in protein biomarker research and development. The company is a provider of contract research services for the identification, validation and application of protein biomarkers. The company's only reportable segment is the sale of goods and biomarker services. The company generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Others.